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Abstract
Background: Hypertensive disorders, i.e. pregnancy induced hypertension and preeclampsia, 
complicate 10 to l5%  o f all pregnancies at term  and are a major cause o f maternal and perinatal 
m orbidity and mortality. The only causal treatm ent is delivery. In case o f preterm pregnancies 
conservative management is advocated if the risks fo r m other and child remain acceptable. In
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contrast, there is no consensus on how to  manage mild hypertensive disease in pregnancies at term. 
Induction o f labour might prevent maternal and neonatal complications at the expense o f increased 
instrumental vaginal delivery rates and caesarean section rates.
Methods/Design: W om en w ith a pregnancy complicated by pregnancy induced hypertension o r 
mild preeclampsia at a gestational age between 36+0 and 41 +0 weeks w ill be asked to  participate in 
a multi-centre randomised controlled trial. W om en will be randomised to  either induction of 
labour o r expectant management fo r spontaneous delivery. The primary outcome o f this study is 
severe maternal morbidity, which can be complicated by maternal m ortality in rare cases. 
Secondary outcome measures are neonatal m ortality and morbidity, caesarean and vaginal 
instrumental delivery rates, maternal quality o f life and costs. Analysis w ill be by intention to  treat. 
In total, 720 pregnant women have to  be randomised to  show a reduction in severe maternal 
complications o f hypertensive disease from  12 to  6%.
Discussion: This tria l w ill provide evidence as to  w hether o r not induction o f labour in women 
w ith pregnancy induced hypertension o r mild preeclampsia (nearly) at term  is an effective 
treatm ent to  prevent severe maternal complications.
T ria l Registration: The protocol is registered in the clinical tria l register number 
ISRCTN08I32825.
Background
Pregnancy induced hypertension and preeclampsia are 
common complications of pregnancy [1]. In many cases, 
the clinical presentation is mild, consisting only of mild 
hypertension and/or mild proteinuria at term. In other 
cases however, severe maternal and fetal complications 
such as eclampsia, abruptio placentae, preterm delivery, 
the Hemolysis Elevated Liver enzymes and Low Platelet 
count syndrome (HELLP), fetal growth restriction or even 
intra-uterine fetal death may occur. Hypertensive disor­
ders in pregnancy make a major contribution to maternal 
and neonatal mortality. In the Netherlands, hypertensive 
disorders in pregnancy are the largest single cause of 
maternal mortality [2].
Approximately 10% to 15% of all pregnancies are compli­
cated by hypertensive disorders. The vast majority of these 
cases occur after 32 weeks. The only causal treatment of 
the disease is delivery. In case of preterm pregnancies (28­
34 weeks gestational age) complicated by preeclampsia 
expectant monitoring is advocated to increase the chance 
of fetal maturity, as long as the risks for the mother remain 
acceptable [3-5]. Expectant management reduces neonatal 
complications and duration of neonatal stay in the inten­
sive care unit in preterm pregnancies and is not associated 
with an increase in maternal complications [4,5].
In case of pregnancy induced hypertension or preeclamp­
sia at term, the situation is different from preterm disease. 
In women with mild preeclampsia complications such as 
abruptio placenta and small for gestational age are similar 
to normotensive pregnancies. It is unclear whether in this 
situation expectant management is beneficial for the 
mother and her baby, since evidence is lacking. Despite
this lack of evidence delivery is often recommended 
because of the unpredictability of the disease [4,6]. Recent 
observational studies indicate that the onset of mild ges­
tational hypertension or mild preeclampsia at or near 
term is associated with minimal to low maternal and neo­
natal morbidity [6-8]. Despite the lack of evidence that 
would justify intervention, many obstetricians induce 
labour in women at term with pregnancy-induced hyper­
tension or preeclampsia. Such a policy may increase the 
risk of assisted vaginal delivery and caesarean section, 
thus generating additional morbidity and costs [9-11]. On 
the other hand, expectant management might lead to 
severe pregnancy complications like eclampsia, severe 
hypertension, HELLP syndrome, organ failure or an 
adverse neonatal outcome.
Data from the Dutch National Obstetric Registration from 
2002 showed that the yearly number of patients with 
hypertension (blood pressure [BP] diastolic above 90 
mmHg) without proteinuria at term is 17.000. Moreover, 
there are 2.000 women with preeclampsia at term. The 
lack of consensus is demonstrated by the fact that in 9.000 
women with pregnancy induced hypertension or preec­
lampsia labour was induced, whereas labour started spon­
taneously in 10.000 women. Moreover, national data 
indicate no impact of induction of labour on neonatal 
outcome. In 2002 and 2003, the rate of babies born with 
a 5-minute Apgar score below 7 was 1.3% among women 
that delivered after a spontaneous onset of labour, versus 
1.6% among women in whom labour was induced (OR 
1.2 95% CI 1.0 to 1.5). After adjustment for potential con- 
founders such as fetal weight, proteinuria and diastolic 
blood pressure, this difference became statically insignifi­
cant despite the analysis of over 35.000 patients (OR 1.1
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95% CI 0.98 to 1.2). Since this equivalence is also 
expected from the pathophysiological background of the 
problem as well as from the medical literature, we antici­
pate no differences in neonatal outcome between both 
strategies.
Data from the Dutch National Obstetric Registration from 
Januari 2000 until Januari 2005 show that 38.170 nulli­
para had a singleton pregnancy in cephalic presentation 
complicated with pregnancy induced hypertension or 
preeclampsia. In 18.012 women labour started spontane­
ously, whereas in 18.810 labour was induced. The non­
elective caesarean section rate among women in whom 
labour started spontaneously was 14% and among 
women in whom labour was induced this rate was 22% 
(OR 1,7 95% CI 1,6 to 1,8). The vaginal instrumental 
delivery rates among these groups were 28% and 24% 
(OR 0,88 95% CI 0,84 to 0,93).
At present, there is no evidence on the effectiveness and 
efficiency of induction of labour in women with preg­
nancy induced hypertension or mild preeclampsia 
(nearly) at term as compared with expectant management 
with close monitoring. In post term women and women 
with ruptured membranes at term, randomised trials have 
indicated that induction of labour does not increase the 
instrumental delivery rate [12,13]. However, the fact that 
the women were post term, might implicate that myome­
trial gapjunctions facilitating effective contractions were 
present [12]. These data can not be extrapolated to 
women who are (nearly) at term with pregnancy induced 
hypertension or preeclampsia.
In view of this clinical dilemma, we propose a ran­
domised clinical trial in which a policy of induction of 
labour, if necessary preceded by artificial cervical ripening, 
is compared with a policy of careful expectant monitoring 
in women with pregnancy induced hypertension or mild 
preeclampsia (nearly) at term. At present -  to our knowl­
edge -  no clinical study has been published or undertaken 
to investigate this issue.
Methods/Designs
Aims
The aim of this study is to investigate whether planned 
induction of labour compared with expectant manage­
ment in women with pregnancy induced hypertension or 
mild preeclampsia at term will reduce severe maternal 
morbidity. We hypothesize that induction of labour will 
reduce maternal morbidity and mortality. The study will 
also provide insight on whether induction of labour in 
women with pregnancy induced hypertension or preec­
lampsia (nearly) at term will reduce costs and improve 
quality of life as compared to expectant monitoring.
The proposed research concerns a multi-centre ran­
domised controlled clinical trial in women who have 
pregnancy induced hypertension or mild preeclampsia at 
gestational ages between 36+0 and 41+0 weeks. This study 
is set in a national Obstetric Research Consortium, in 
which 40 obstetric clinics in the Netherlands collaborate. 
Approximately 40 clinics, including academic hospitals, 
non-academic teaching hospitals and non-teaching hospi­
tals will participate in this trial.
Participants/Eligibility criteria
Patients 18 years of age or older will be eligible if they 
have pregnancy induced hypertension or mild preeclamp­
sia at a gestational age between 36+0 and 41+0 weeks of ges­
tation. A diagnosis of pregnancy induced hypertension is 
made in case the diastolic BP is equal to or above 95 
mmHg at two occasions at least six hours apart in a 
woman who was normotensive at the start of pregnancy 
until week 20 of gestational age. A diagnosis of mild 
preeclampsia is made in case the diastolic BP is above 90 
mmHg and there exists a proteinuria > 300 mg total pro­
tein in a 24 hour urine collection. Women with a single­
ton pregnancy in cephalic presentation are eligible. 
Excluded were women with severe pregnancy induced 
hypertension or preeclampsia (diastolic BP > 110 mmHg, 
systolic BP > 170 mmHg and/or proteinuria > 5 gram in 
24 hours), pre-existing hypertension (BP before 20 weeks 
of gestation > 140/90 mmHg and/or using antihyperten­
sive medication), diabetes mellitus, diabetes gravidarum 
requiring insulin therapy, renal disease, heart disease, 
HIV-seropositivity, intravenous anti-hypertensive medica­
tion, a previous caesarean section, HELLP syndrome, olig­
uria < 500 milliliter in 24 hours, pulmonary edema or 
cyanosis, fetal disorders, and abnormalities at the fetal 
heart rate (FHR) -monitoring are not eligible for the study.
Procedures, recruitment, randomisation and collection o f  
baseline data
Eligible women will be identified by the research coordi­
nator and/or the staff of participating hospitals. These 
women will be referred to a research midwife or research 
nurse for counselling. Before entry into the study this per­
son will explain to potential subjects the aims, methods, 
reasonably anticipated benefits, and potential hazards of 
the study. Subjects will be informed that their participa­
tion is voluntary and that they may withdraw consent to 
participate at any time during the study. They will be 
informed that choosing not to participate will not affect 
their care. In every centre an independent gynaecologist 
will be available for more detailed information both for 
patients and colleagues if required. After giving sufficient 
information written informed consent has to be obtained. 
The consent form must be signed before performance of 
any study-related activity. Patients who decide not to par­
ticipate in this study will be treated according to one of the
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two protocols at the discretion of the attending obstetri­
cian and analysed separately.
The study will be an open label study, as it is impossible 
to blind the health care workers involved for the strategy 
to which the woman is allocated. Cross-over between the 
two strategies would complicate the interpretation of 
study result. Although it will not be possible to prevent all 
cross-overs, both strategies will be performed according to 
strict criteria, as mentioned below.
After a patient has given informed consent for participa­
tion in the study cervical length will be measured using 
transvaginal sonography, and vaginal examination will be 
performed (Bishop score), both to assess cervical ripeness. 
At study entry all women will have baseline demographic, 
past obstetric and medical history recorded. After explana­
tion of the study and informed consent, but prior to ran­
domisation, we will perform a baseline measurement for 
quality of life (SF-36, HADS, EuroQol 6D3L) and addi­
tional questions on intervention preparedness and per­
sonal experience of the pregnancy. Subsequently, the 
patient will be randomised to either a policy that aims ter­
mination of pregnancy (intervention group) or a policy 
that aims expectant management for spontaneous deliv­
ery (expectant group). Randomisation will be performed 
through a web-based database which is hosted at the Aca­
demic Medical Centre (AMC) in Amsterdam. Randomisa­
tion will be 1:1 for intervention and expectant 
management, and it will be stratified for centre, parity and 
proteinuria according to the criteria above. Patients fill 
out additional quality of life questionnaires 6 weeks after 
delivery and 6 months after delivery (SF-36, HADS, Euro- 
QoL 6D3L, SCL-90) and additional questions on personal 
experience of the delivery.
At local centres data-collection will be the responsibility 
of the local research coordinator and the regional research 
midwives or nurses. The data collected in this study will 
be coded and processed with adequate precautions to 
ensure patient confidentially.
Interventions
Intervention group
In the intervention group, patients will be induced 
within 24 hours after randomisation. In patients with a 
Bishop cervix score > 6 at vaginal examination labour will 
be induced by amniotomy and, if needed, augmentation 
with oxytocin. If this score is 6 or lower cervical ripening 
will be stimulated with use of intracervical or intravaginal 
prostaglandins according to the local protocol. In case the 
cervix is judged to be unripe the day after 'priming', the 
cervical ripening will be repeated. If the cervix remains 
'unripe', day 3 will be a rest day. Cervical ripening will be
repeated at day 4 and 5. All patients in the intervention 
group will be monitored clinically until after delivery.
Expectant group
In the expectant group, patients will be monitored until 
the onset of spontaneous delivery. Monitoring will consist 
of assessment of fetal movements as reported by the 
mother, as well as electronic FHR-monitoring according 
to the local protocol. Maternal evaluation consists prima­
rily of frequent evaluation of blood pressure measure­
ment and screening of urine for protein using a dipstick or 
protein/creatinin ratio and 24 hour urine collection for 
protein in case of positive screening. Blood tests (platelet 
count, liver enzymes and renal function) will be per­
formed according to the local protocol.
In the expectant monitoring group, intervention is recom­
mended in case fetal condition does not justify expectant 
management anymore (no fetal movements reported by 
the mother, non-optimal FHR-monitoring). Moreover, 
induction of labour is recommended in case the diastolic 
blood pressure is > 110 mmHg or the systolic blood pres­
sure is > 170 mmHg, in case 24 hours proteinuria exceeds 
5 gram, in case intravenous anti-hypertensive or prophy­
lactic anti-convulsive medication is started, in case 
eclampsia or the HELLP syndrome occurs. In case in the 
expectant group any other indication rises for induction 
of labour, for example prelabour rupture of membranes 
for > 24 hours or meconium stained liquor, patients will 
be induced.
Follow up o f women and infants
All details of delivery, maternal assessments and admis­
sion during pregnancy are recorded in the case record 
form that is accessible through the website. Maternal mor­
tality and morbidity will be specified until date of dis­
charge from hospital and six weeks postpartum. In case of 
admittance of the baby to the neonatal intensive care, 
high care, medium care unit or maternal ward, details of 
this admission are also documented. Neonatal mortality 
and morbidity will be specified until date of discharge 
from hospital. We will register the diagnosis at discharge: 
small for gestational age, hypoglycemia, respiratory dis­
tress syndrome, chronic lung disease, meconium aspira­
tion, pneumothorax, apneu, asphyxia, necrotizing 
enterocolitis, intraventicular hemorrhage, periventricular 
leucomalacia, neonatal sepsis and neonatal meningitis.
A plan for long-term follow up of the mothers is in prep­
aration. Long-term follow up of children will not be per­
formed, because we do not expect differences between 
both policies during childhood.
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Outcome measures
Primary outcome m easure
The primary outcome measure will be severe maternal 
morbidity, which can be complicated by maternal mortal­
ity in rare cases. Severe maternal morbidity will be defined 
as diastolic BP > 110 mmHg, systolic BP > 170 mmHg, 
major postpartum hemorrhage, eclampsia, HELLP syn­
drome, pulmonary edema, trombo-embolic disease and/ 
or abruptio placentae [14]. Major postpartum hemor­
rhage is defined as blood loss > 1000 ml within 24 hours 
after delivery [15]. Eclampsia is defined as severe preg­
nancy induced hypertension or preeclampsia resulting in 
maternal seizures [16]. HELLP syndrome is defined as a 
complication of severe preeclampsia involving Hemoly­
sis, Elevated Liver functions, and Low Platelets [17]. 
Trombo-embolic disease is defined as deep-vein throm­
bosis, pulmonary embolism or both. Patients will be 
examined for deep-vein thrombosis byduplex dopplerif 
thrombosis is suspected from clinical examination. A 
diagnosis of pulmonary embolism will be confirmed by 
pulmonary angiography, computed tomography, mag­
netic resonance imaging or a ventilation-perfusion lung 
scan [18-20].
Secondary outcome m easures
Secondary outcomes will be neonatal mortality or neona­
tal morbidity, caesarean section rate, instrumental vaginal 
delivery rate, maternal quality of life and quality of recov­
ery and costs. Adverse neonatal outcome will be defined 
as a 5-minute Apgar score below 7, an umbilical artery pH 
below 7.05 or admission to the neonatal intensive care.
Statistical issues
Sample size
The aim of induction of labour is to reduce the rate of 
severe complications of hypertensive disease, such as 
postpartum hemorrhage, sever hypertension (diastolic BP 
> 110 mmHg), eclampsia and HELLP syndrome. In 
women with a singleton pregnancy in cephalic presenta­
tion at term (>36 weeks), the prevalence of such compli­
cations in 2003 and 2004 was 12% [21]. To our opinion, 
the disadvantages of induction of labour outweigh the 
advantages when the complication rate is reduced to 6%. 
In order to detect such a difference, we will need two 
groups of 360 patients (two-sided test, alpha .05; beta 
.80).
Data analysis
The analysis will be performed by intention to treat, and 
stratified for centre, parity and for underlying disease 
(preeclampsia or pregnancy induced hypertension). 
Quality of life as well as pain scores will be analysed using 
repeated measures analysis of variance [22]. Relative risks 
and 95% confidence intervals will be calculated for the 
relevant outcome measures.
Moreover, we will evaluate whether the relative benefits of 
induction of labour will be stronger in women with a ripe 
cervix at baseline and in women with a short cervical 
length at transvaginal sonography. In case of equivalence 
between outcomes, the analysis will be repeated on a par 
protocol basis.
Economic analysis
The process of care is distinguished into three cost stages 
(antenatal stage, delivery/childbirth, postnatal stage) and 
three cost categories (direct medical costs [all costs in the 
health care sector], direct non-medical costs [costs outside 
the health care sector that are affected by health status or 
health care] and indirect costs of the pregnant women and 
her partner [costs of sick level]). For each stage and each 
cost category, costs are measured as the volumes of 
resources used multiplied with appropriate valuations 
(cost-per-unit estimates, fees, national reference prices). 
Cost volumes in the antenatal stage consist of direct med­
ical costs (e.g. home/hospital care, outpatients' visits, fetal 
monitoring [FHR-monitoring, ultrasound, Doppler] and 
maternal monitoring [various lab tests; hospital care]). 
Direct non-medical and indirect costs in that stage may 
occur if role patterns or household routines shift. As we 
anticipate an improvement of between maternal out­
comes after induction of labour the economic analysis is 
expected to be a cost-effectiveness analysis.
Serious adverse events will be reported to an independ­
ent data safety monitoring committee. A formal interim 
analysis is not planned.
Ethical considerations The study protocol has been 
approved by the Medical Ethical Committee of the Uni­
versity Medical Centre of Leiden (p04.210). The protocol 
is registered in the clinical trial register number 
ISRCTN08132825.
Discussion
Pregnancy induced hypertension and preeclampsia are 
important hypertensive disorders during pregnancy which 
are associated with increased maternal and neonatal mor­
bidity and mortality. There is no consensus on how to 
manage mild hypertensive diseases at term. Induction of 
labour might prevent maternal complications, but is also 
thought to increase the caesarean and vaginal instrumen­
tal delivery rate. This trial is designed to provide evidence 
on the effectiveness of induction of labour in women with 
mild pregnancy induced hypertension or preeclampsia 
(nearly) at term to prevent severe maternal and neonatal 
complications.
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